American CryoStem Awarded Patent for Cell Culture Media
September 01 2011 - 9:00AM
Marketwired
American CryoStem Corporation (OTCBB: CRYO) announced the grant to
it of a patent by the United States Patent Office (USPTO).
American CryoStem Corporation (the "Company") has been awarded
U.S. Patent Number 7,989,205, entitled "Cell Culture Media, Kits,
and Methods of Use" (the "Patent"), by the USPTO. This Patent
covers a unique product for cellular growth in the processing of
adult stem cells. This is significant to the Company for the
advancement of its research, clinical and cosmetic applications.
The Company's management believes that the Patent will support the
Company's efforts in its goal to establish itself as a leader in
the preparation of autologous stem cells for use in regenerative
medicine. The Patent includes a specific human formulation to
overcome the concerns and issues prevalent in the FDA's and other
regulatory agencies' guidance when using non-human biologic
materials in the preparation of stem cells for human use.
John S Arnone, CEO, stated, "We are pleased to have the Patent
granted to the Company by the USPTO. We believe the Patent will be
instrumental to the industry based on its cellular growth
properties and absence of non-human biologic material. Further, as
stem cell and regenerative medicine advances in the United States,
as it has globally, the Company is confident the Patent, together
with our core technology and our intellectual property regarding
methods, formulations, devices and products will allow us to enter
into additional partnerships and collaborations with other industry
participants. The Patent validates our corporate direction and
enhances our strategy to obtain strong intellectual property
protection."
Anthony Dudzinski, COO, stated, "We believe the Patent on specie
specific media gives the Company a unique market position by
alleviating the significant regulatory requirements associated with
products containing fetal bovine serum or other non-human biologic
components. The Patent is important and will accelerate the
development and commercialization of additional Company products
and services. We are excited and very optimistic regarding our
place in the stem cell industry and the value of our products and
services."
About American CryoStem: The Company
markets a core clinical processing platform for Adipose (fat)
Derived Adult Stem Cells. The Company's services provide for the
collection, processing, and cryopreservation (long term storage) of
adult stem cells, allowing healthy individuals to privately
preserve their stem cells for future use in personalized and
regenerative medicine at an affordable price. Adult stem cell
treatments are currently being utilized to potentially heal one's
own body of diseases and chronic conditions. The Company's
proprietary platform provides streamlined and affordable processing
and cryopreservation of Adipose Derived Stem Cells and Adipose
Tissue for autologous (self) use.
Contact: American CryoStem Corporation 188 East Bergen Place,
Suite 204 Red Bank, NJ 07701 732-747-1007
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jul 2023 to Jul 2024